Skip to main content
FR

CHRONIC IMMUNOLOGICAL DISEASES AND TREATMENT FAILURE

Chronic immunological diseases require treatment over an extended period of time. After a while, the brand name biologic or biosimilar treatment might stop working for a particular patient – this is called a “treatment failure”.1

Clinical trials have shown that a substantial proportion of patients
experience treatment failure
. This can result from patients:2

  • Failing to respond to treatment or having an inadequate response (called “primary failure”)

  • Losing response to treatment over time (called “secondary failure”)

  • Developing an adverse event

Treatment failure often results in patients switching to a different biologic therapy.3

For example, in rheumatoid arthritis, international treatment guidelines recommend that a new biologic therapy be considered after treatment failure, either from the same biologic class (i.e., the same target) or a different class (i.e., a new target) altogether.3

After treatment failure, patients may be
SWITCHED TO A BIOLOGIC TREATMENT
OPTION
that has a DIFFERENT TARGET3

Patients may require MULTIPLE BRAND NAME BIOLOGICS AND BIOSIMILARS over the course of their disease

Jump to top of page